Physician profile
Mark K Ono
NPI 1427022144
$4,006.16
in general payments reported to CMS, 2019-2025
35 companies · $28.44 in 2025
The $28.44 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $602 · 2021: $1,545 · 2022: $319 · 2023: $71.18 · 2024: $568 · 2025: $28.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $525 · Food and Beverage: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $525.00 |
| Food and Beverage | $142.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $835.80 | 2019-2024 | Imfinzi |
| Janssen Biotech, INC. | $488.48 | 2019-2024 | Erleada |
| Novartis Pharmaceuticals Corporation | $422.34 | 2019-2021 | |
| Genzyme Corporation | $215.44 | 2019-2021 | |
| Astellas Pharma US INC | $172.47 | 2019-2023 | Xtandi |
| Abbvie INC. | $166.11 | 2019-2022 | |
| Amgen INC. | $152.10 | 2019-2021 | |
| Seagen INC. | $151.07 | 2019-2022 | |
| Novocure INC. | $144.06 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $142.65 | 2020-2022 | |
| Lilly USA, LLC | $127.82 | 2021 | |
| Elekta, INC. | $125.18 | 2021 | |
| Glaxosmithkline, LLC. | $104.60 | 2020-2025 | Jemperli |
| E.R. Squibb & Sons, L.L.C. | $69.38 | 2021-2022 | |
| Eisai INC. | $62.27 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $60.99 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.12 | 2019-2024 | |
| Dova Pharmaceuticals | $51.34 | 2019-2021 | |
| Mylan Institutional INC. | $49.60 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $45.43 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $41.04 | 2020-2021 | |
| Clovis Oncology, INC. | $37.52 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $35.87 | 2019 | |
| Genentech USA, INC. | $33.39 | 2019 | |
| Blueprint Medicines Corporation | $31.54 | 2020-2021 | |
| Shire North American Group INC | $30.58 | 2019 | |
| Boston Scientific Corporation | $25.47 | 2021 | |
| Epizyme, INC. | $21.97 | 2020 | |
| Incyte Corporation | $18.07 | 2020 | |
| Myovant Sciences INC. | $16.63 | 2021 | |
| Daiichi Sankyo INC. | $16.61 | 2021 | |
| Puma Biotechnology, INC. | $15.49 | 2020 | |
| Pfizer INC. | $15.29 | 2020 | |
| Amag Pharmaceuticals, INC. | $14.62 | 2020 | |
| Verastem, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ono listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.